Citigroup Inc Belite Bio, Inc Call Options Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
23Shares Held
282KCall Options Held
0Put Options Held
0-
Rtw Investments, LP New York, NY313KShares$33.1 Million0.31% of portfolio
-
Marshall Wace, LLP London, X0188KShares$19.8 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA15.6KShares$1.65 Million0.0% of portfolio
-
State Street Corp Boston, MA13.3KShares$1.4 Million0.0% of portfolio
-
Ubs Group Ag11.3KShares$1.2 Million0.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.63B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...